Видео ютуба по тегу Summit Therapeutics Drug Trial

Summit Therapeutics Co-CEOs on what's next for lung cancer drug
Summit Therapeutics Co-CEOs on what's next for lung cancer drug
Terns CEO Amy Burroughs talks cancer drug trial win
Terns CEO Amy Burroughs talks cancer drug trial win
Summit Therapeutics Data From The Phase III HARMONi Trial Of Ivonescimab | Sep 08, 2025
Summit Therapeutics Data From The Phase III HARMONi Trial Of Ivonescimab | Sep 08, 2025
Summit Therapeutics passes “important milestone” with FDA approval
Summit Therapeutics passes “important milestone” with FDA approval
Summit Therapeutics (C1100) [PPMD's 2015 Connect Conference]
Summit Therapeutics (C1100) [PPMD's 2015 Connect Conference]
Glyn Edwards of Summit Therapeutics Discusses the PhaseOut DMD Trial
Glyn Edwards of Summit Therapeutics Discusses the PhaseOut DMD Trial
Glyn Edwards of Summit Therapeutics Discusses Endpoints of DMD Trials
Glyn Edwards of Summit Therapeutics Discusses Endpoints of DMD Trials
Summit Therapeutics CEO says anti microbial resistance will be as big a problem as climate change
Summit Therapeutics CEO says anti microbial resistance will be as big a problem as climate change
Updates in EGFR-Mutated Non-Small Cell Lung Cancer - Lung Cancer Key Developments OncPanel 2025-26
Updates in EGFR-Mutated Non-Small Cell Lung Cancer - Lung Cancer Key Developments OncPanel 2025-26
Summit Therapeutics
Summit Therapeutics "can alter treatment paradigm" for CDI
Summit Therapeutics aiming to 'make a big impact' with new drug Ridinilazole
Summit Therapeutics aiming to 'make a big impact' with new drug Ridinilazole
Summit Therapeutics to begin Phase 3 studies of ridinilazol this quarter
Summit Therapeutics to begin Phase 3 studies of ridinilazol this quarter
NGS Testing for MTAP Loss - Lung Cancer Key Developments OncPanel 2025-26
NGS Testing for MTAP Loss - Lung Cancer Key Developments OncPanel 2025-26
Большой риск — большая награда. Новое лекарство от рака. Анализ Summit Therapeutics, акции SMMT |...
Большой риск — большая награда. Новое лекарство от рака. Анализ Summit Therapeutics, акции SMMT |...
Summit Therapeutics (SMMT) Stock Drops 11.82% Despite Q3 Earnings Beat Amid Rising R&D Expenses
Summit Therapeutics (SMMT) Stock Drops 11.82% Despite Q3 Earnings Beat Amid Rising R&D Expenses
Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?
Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?
Summit Therapeutics Inc. (NASDAQ: SMMT) Q3 2025 Earnings Call | 10/20/2025
Summit Therapeutics Inc. (NASDAQ: SMMT) Q3 2025 Earnings Call | 10/20/2025
Summit Therapeutics ‘keeping up drug development pace’ following $22mln milestone payment
Summit Therapeutics ‘keeping up drug development pace’ following $22mln milestone payment
[Fullver] Summit Therapeutics Inc. Mystery: Why is the FDA Data Diverging? Trading Tips 📉
[Fullver] Summit Therapeutics Inc. Mystery: Why is the FDA Data Diverging? Trading Tips 📉
Glyn Edwards of Summit Therapeutics Provides an Update on the PhaseOut DMD Trial
Glyn Edwards of Summit Therapeutics Provides an Update on the PhaseOut DMD Trial
Summit Therapeutics Q3 2025: FDA Fight Sparks Stock Sell-Off
Summit Therapeutics Q3 2025: FDA Fight Sparks Stock Sell-Off